Delivery of nasal powders of beta-cyclodextrin by insufflation

Pharm Res. 1996 May;13(5):734-8. doi: 10.1023/a:1016099516757.

Abstract

Purpose: Delivery of nasal powders of granulated beta-cyclodextrin by insufflation was studied in order to find the relationship between powder properties and delivery behavior.

Methods: Three nasal powder formulations, prepared by granulating beta-cyclodextrin with different binders, were delivered from a powder insufflation device, in which the dose to be emitted was loaded in a gelatin capsule. The delivery sequence of powder was recorded and characterized using an image analysis program.

Results: Particle size was the main parameter affecting nasal powder delivery, both as to the amount of dose sprayed and the aspect of cloud produced. Between 50-150 mu m of particle size a substantial change in delivery behavior of powders was observed. Powder of around 100 mu m in size showed useful insufflation characteristics for nasal delivery. Bioavailability of nasal formulations of progesterone/beta-cyclodextrin powders was discussed in term of delivery behavior.

Conclusions: The formulation approaches for improving nasal delivery of powders require the use of size optimized carriers. Insufflation of powders over 50 mu m can favour the particle deposition by impaction, whereas for powders below 50 mu m, deposition by sedimentation is moved. beta-cyclodextrin is a suitable carrier for achieving high systemic availability following nasal administration of powder formulations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Biological Availability
  • Cyclodextrins / administration & dosage*
  • Drug Carriers
  • Insufflation
  • Powders
  • Progesterone / administration & dosage
  • Progesterone / pharmacokinetics*
  • Rabbits
  • beta-Cyclodextrins*

Substances

  • Cyclodextrins
  • Drug Carriers
  • Powders
  • beta-Cyclodextrins
  • Progesterone
  • betadex